HRP20050689A2 - 4-aminopyrimidine-5-one - Google Patents

4-aminopyrimidine-5-one

Info

Publication number
HRP20050689A2
HRP20050689A2 HR20050689A HRP20050689A HRP20050689A2 HR P20050689 A2 HRP20050689 A2 HR P20050689A2 HR 20050689 A HR20050689 A HR 20050689A HR P20050689 A HRP20050689 A HR P20050689A HR P20050689 A2 HRP20050689 A2 HR P20050689A2
Authority
HR
Croatia
Prior art keywords
compounds
dependent kinase
cyclin
cancer
formula
Prior art date
Application number
HR20050689A
Other languages
English (en)
Croatian (hr)
Inventor
Joseph Barkovitz David
Chu Xin-Jie
Ding Qingjie
Jiang Nan
Allen
Anthony Moliterni John
John
Thanh Vu Binh
Michael Wovkulich Peter
Original Assignee
F. Hoffmann - La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann - La Roche Ag filed Critical F. Hoffmann - La Roche Ag
Publication of HRP20050689A2 publication Critical patent/HRP20050689A2/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48Two nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HR20050689A 2003-02-10 2005-08-01 4-aminopyrimidine-5-one HRP20050689A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US44627303P 2003-02-10 2003-02-10
US51492603P 2003-10-28 2003-10-28
PCT/EP2004/000971 WO2004069139A2 (en) 2003-02-10 2004-02-03 4-aminopyrimidin-5-yl-methanone derivatives for inhibition of cdk4 activity

Publications (1)

Publication Number Publication Date
HRP20050689A2 true HRP20050689A2 (en) 2006-08-31

Family

ID=32853425

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20050689A HRP20050689A2 (en) 2003-02-10 2005-08-01 4-aminopyrimidine-5-one

Country Status (22)

Country Link
US (2) US7157455B2 (xx)
EP (1) EP1628619A2 (xx)
JP (1) JP2006523183A (xx)
KR (1) KR100717099B1 (xx)
AR (1) AR043693A1 (xx)
AU (1) AU2004210408A1 (xx)
BR (1) BRPI0407381A (xx)
CA (1) CA2512915A1 (xx)
CL (1) CL2004000226A1 (xx)
EA (1) EA009412B1 (xx)
EC (1) ECSP055958A (xx)
HR (1) HRP20050689A2 (xx)
IL (1) IL169626A0 (xx)
MA (1) MA27716A1 (xx)
MX (1) MXPA05008333A (xx)
MY (1) MY137555A (xx)
NO (1) NO20053410L (xx)
PL (1) PL382309A1 (xx)
RS (1) RS20050610A (xx)
TN (1) TNSN05188A1 (xx)
TW (1) TWI293881B (xx)
WO (1) WO2004069139A2 (xx)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7211576B2 (en) * 2004-04-20 2007-05-01 Hoffmann-La Roche Inc. Diaminothiazoles
US7405220B2 (en) 2004-06-09 2008-07-29 Hoffmann-La Roche Inc. Pyrazolopyrimidines
ES2313556T3 (es) * 2005-05-25 2009-03-01 F. Hoffmann-La Roche Ag Biomarcador para el control de la respuesta de los inhibidores de la cdk en la clinica.
US7705009B2 (en) * 2005-11-22 2010-04-27 Hoffman-La Roche Inc. 4-aminopyrimidine-5-thione derivatives
BRPI0619236A2 (pt) 2005-12-01 2011-09-20 Hoffmann La Roche derivados de 2,4,5-trifenil imidazolina, composição farmacêutica que os compreende, uso e processo para a sìntese dos mesmos
WO2007113005A2 (en) * 2006-04-03 2007-10-11 European Molecular Biology Laboratory (Embl) 2-substituted 3-aminosulfonyl-thiophene derivatives as aurora kinase inhibitors
EP2343974A4 (en) 2008-08-15 2015-07-15 Univ Georgetown SODIUM CHANNELS, DISEASE, AND ASSAYS AND RELATED COMPOSITIONS
US9133123B2 (en) 2010-04-23 2015-09-15 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
HUE045748T2 (hu) * 2014-07-01 2020-01-28 Millennium Pharm Inc Heteroaril vegyületek mint SUMO aktiváló enzimek inhibitorai
CN113924293B (zh) 2019-06-06 2024-07-09 北京泰德制药股份有限公司 P2x3和/或p2x2/3受体拮抗剂、包含其的药物组合物及其用途
EP4289835A4 (en) * 2021-02-05 2024-08-28 Shanghai Qilu Pharmaceutical Res And Development Centre Ltd CDK INHIBITORS
WO2024063670A1 (ru) * 2022-09-22 2024-03-28 Акционерное общество "БИОКАД" Ингибиторы циклинзависимой киназы 7

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9012592D0 (en) 1990-06-06 1990-07-25 Smithkline Beecham Intercredit Compounds
WO1998033798A2 (en) * 1997-02-05 1998-08-06 Warner Lambert Company Pyrido[2,3-d]pyrimidines and 4-amino-pyrimidines as inhibitors of cell proliferation
SK5212000A3 (en) 1997-10-27 2001-04-09 Agouron Pharmaceuticals Inc Ag 4-aminothiazole derivatives, their preparation and their use as inhibitors of cyclin-dependent kinases
US6262096B1 (en) * 1997-11-12 2001-07-17 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
EA200000840A1 (ru) 1998-02-17 2001-02-26 Туларик, Инк. Антивирусные производные пиримидина
AU5438299A (en) 1998-08-29 2000-03-21 Astrazeneca Ab Pyrimidine compounds
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
MXPA02001108A (es) 1999-09-15 2002-08-20 Warner Lambert Co Pieridinonas como inhibidores de la cinasa.
CA2386955A1 (en) 1999-11-22 2001-05-31 Warner-Lambert Company Quinazolines and their use for inhibiting cyclin-dependent kinase enzymes
PE20011066A1 (es) * 2000-01-25 2001-10-22 Warner Lambert Co PIRIDO [2,3-d] PIRIMIDIN-2,7-DIAMINAS INHIBIDORES DE CINASAS
SK10772002A3 (sk) * 2000-01-27 2004-01-08 Warner-Lambert Company Pyridopyrimidinónové deriváty na liečbu neurodegeneratívnych ochorení
GB0004886D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004888D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
JP2004501083A (ja) 2000-04-18 2004-01-15 アゴーロン・ファーマシューティカルズ・インコーポレイテッド プロテインキナーゼを阻害するためのピラゾール
JP4105948B2 (ja) 2000-09-15 2008-06-25 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼインヒビターとして有用なピラゾール化合物
KR100909665B1 (ko) 2000-12-21 2009-07-29 버텍스 파마슈티칼스 인코포레이티드 단백질 키나제 억제제로서 유용한 피라졸 화합물 및 이를 포함하는 약제학적 조성물
WO2002096888A1 (de) * 2001-05-29 2002-12-05 Schering Aktiengesellschaft Cdk inhibitorische pyrimidine, deren herstellung und verwendung als arzneimittel
US7288547B2 (en) * 2002-03-11 2007-10-30 Schering Ag CDK-inhibitory 2-heteroaryl-pyrimidines, their production and use as pharmaceutical agents
EA200500721A1 (ru) 2002-11-28 2005-12-29 Шеринг Акциенгезельшафт Пиримидины, ингибирующие chk, pdk и акт, их получение и применение в качестве лекарственных средств
CA2515095A1 (en) 2003-02-10 2004-08-19 Pfizer Inc. Regimen of administration for nelfinavir
RU2373937C9 (ru) 2003-02-10 2010-07-27 Байер Шеринг Фарма Акциенгезельшафт Лечение бактериальных заболеваний органов дыхания путем местного применения фторхинолонов
DE10349423A1 (de) 2003-10-16 2005-06-16 Schering Ag Sulfoximinsubstituierte Parimidine als CDK- und/oder VEGF-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel

Also Published As

Publication number Publication date
EA009412B1 (ru) 2007-12-28
CA2512915A1 (en) 2004-08-19
TNSN05188A1 (en) 2007-06-11
EP1628619A2 (en) 2006-03-01
IL169626A0 (en) 2007-07-04
US7157455B2 (en) 2007-01-02
WO2004069139A3 (en) 2007-04-26
KR20050099544A (ko) 2005-10-13
CL2004000226A1 (es) 2005-01-14
AR043693A1 (es) 2005-08-10
MXPA05008333A (es) 2005-09-30
JP2006523183A (ja) 2006-10-12
MA27716A1 (fr) 2006-01-02
ECSP055958A (es) 2006-01-16
KR100717099B1 (ko) 2007-05-10
RS20050610A (xx) 2007-12-31
US20060229330A1 (en) 2006-10-12
MY137555A (en) 2009-02-27
WO2004069139A2 (en) 2004-08-19
NO20053410L (no) 2005-09-08
PL382309A1 (pl) 2007-08-20
TWI293881B (en) 2008-03-01
EA200501233A1 (ru) 2006-04-28
US20040162303A1 (en) 2004-08-19
TW200423940A (en) 2004-11-16
US7615634B2 (en) 2009-11-10
AU2004210408A1 (en) 2004-08-19
BRPI0407381A (pt) 2006-02-07

Similar Documents

Publication Publication Date Title
HRP20050689A2 (en) 4-aminopyrimidine-5-one
BRPI0408068A (pt) derivados de 5-feniltiazol e seus usos como inibidores de pi3 cinase
MX2022013223A (es) [1,3]diazino[5,4-d]pirimidinas como inhibidores de her2.
BR112022012641A2 (pt) Compostos tricíclicos substituídos
MY156407A (en) 5-phenylthiazole derivatives and use as p13 kinase inhibitors
MX2010003927A (es) Derivados de pirrolo [2,3-d] pirimidina como inhibidores de proteinas cinasas b.
AR058780A1 (es) Imidazopirazinas como inhibidores de quinasas dependientes de ciclina
UA86614C2 (ru) Соединение, которое имеет активность ингибитора киназ, фармацевтическая композиция, которая включает указанное соединение, и их применение для приготовления лекарственного препарата
BRPI0618552B8 (pt) compostos derivados de pirimidina ligados ao oxigênio,composição farmacêutica que inclui os ditos compostos,método de síntese dos compostos e usos terapêuticos dos mesmos
MY147677A (en) Piperazinyl derivatives useful in the treatment of gpr38 receptor mediated diseases
AU2006273692A8 (en) 1,4-Dihydropyridine-fused heterocycles, process for preparing the same, use and compositions containing them
CL2003002565A1 (es) Compuestos derivados de 3h-quinazolin-4-ona, su proceso de preparacion, composicion farmaceutica que los contiene, y uso en el tratamiento y prevencion de enfermedades mediadas por inhibidores de mao-b, tales como la enfermedad de alzheimer y demenci
SA522441965B1 (ar) Trpa1 مشتقات تترازول كمثبطات لـ
WO2007068473A3 (en) Organic compounds
BRPI0409818A (pt) compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos
MX2023011829A (es) Derivados de uracilo como inhibidores de trpa1.
MX2023014784A (es) Preparacion de derivados de compuestos 1,2-diaminoheterociclicos sustituidos y su uso como agentes farmaceuticos.
MX2023006881A (es) Antagonistas del receptor de adenosina a2a.
SA522441973B1 (ar) Trpa1 مشتقات تترازول كمثبطات لـ
MX2023003516A (es) Inhibidores no covalentes de la cinasa dependiente de ciclina 7 (cdk7).
WO2002059109A3 (en) Naphthostyril derivatives and their use as inhibitors of cyclin- dependent kinases
WO2004108094A3 (en) Sulfonamide-substituted chalcone derivatives and their use to treat diseases
SA523440367B1 (ar) مشتقات تترازول كمثبطات لمستقبل عابر أنكيرين قوي 1
UA93878C2 (ru) Производная бензилпиперазина, ee применение при лечении разных расстройств и фармацевтическая композиция, которая ee содержит
BRPI0417895A (pt) derivado de indeno (2,1a)indeno e isoindolo(2,1-a)indole, processo para a preparação de um composto, composições farmacêuticas, uso do derivado, uso de um rádiocomposto identificado e método para um tratamento de prevenção ou um tratamento de desordem

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20080125

Year of fee payment: 5

OBST Application withdrawn